Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL29358021 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL2583823 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL114238 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643985 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1286957 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL8732632 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL15855060 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1560678 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL27799 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643980 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101292967-A | Coating agent for preventing and controlling mentation disorder | ZHONGHUA YUAN (CN) | 2008-10-29 | — | — | CN | claimed |
| US-11839607-B2 | Memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application | HEFEI KEDA BIO-TECHNOLOGY CO. LTD (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20210038590-A1 | MEMANTINE PAROXETINE COCRYSTAL SALT AND ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION | HEFEI KEDA BIO-TECHNOLOGY CO. LTD (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-2052251-B1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-2629615-B1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468627-B2 | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies | DUKE UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | N-GENE RESEARCH LABORATORIES, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9144547-B2 | Oral dosage form for controlled drug release | GLAXO GROUP LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| WO-2015071831-A1 | AN IMPROVED PROCESS FOR MINIMISING THE FORMATION OF DEHALOGENATED BYPRODUCTS | Piramal Enterprises Limited (IN) | 2015-05-21 | — | — | WO | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20060287299-A1 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE J | 2006-12-21 | — | — | US | disclosed |
| US-20060142375-A1 | Method for augmenting the effects of serotonin reuptake inhibitors | DUKE UNIVERSITY | 2006-06-29 | — | — | US | disclosed |
| WO-2006036928-A2 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | WAYNE STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1482939-A4 | PREPARATION OF PAROXETINE INVOLVING NOVEL INTERMEDIATES | TEVA PHARMA (IL) | 2005-10-12 | — | — | EP | disclosed |
| US-20050175700-A1 | Erodable coating around core; for sustained release of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1482939-A1 | PREPARATION OF PAROXETINE INVOLVING NOVEL INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003072104-A1 | PREPARATION OF PAROXETINE INVOLVING NOVEL INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | SLC6A4 56/4885CYP3A4 657/4885GRK2 93/4885 |
| US-11839607-B2 | Memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application | HTR6, HTR2A, HTR2B | SLC6A4 12/4885CYP3A4 1044/4885GRK2 67/4885 |
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | GRM5, GRIK5, GRIN2A | SLC6A4 149/4885CYP3A4 1980/4885GRK2 1547/4885 |
| US-20210038590-A1 | MEMANTINE PAROXETINE COCRYSTAL SALT AND ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION | HTR6, HTR2A, HTR2B | SLC6A4 12/4885CYP3A4 1044/4885GRK2 67/4885 |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | TPH1, HTR5A, TPH2 | SLC6A4 13/4885CYP3A4 1271/4885GRK2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.